Company intelligence / Profile preview

VectivBio

Ownership: Public · VECT
Employees: ~75
Development stage: Phase 3

Overview

Apraglutide demonstrated compelling data in Phase II and was in Phase III trials targeting SBS‑IF, with potential best-in-class profile due to weekly dosing and broad patient applicability. The CoMET small molecule platform aimed to address previously undruggable inherited metabolic disorders by restoring cellular metabolism.

Therapeutic areas: GastroenterologyImmunologyMetabolic Disorders
Modalities: Peptide analogsSmall molecules
Industry: Biotech

Drug pipeline

1 asset

apraglutide

Phase 3

Indications: Short Bowel Syndrome with Intestinal Failure, Acute Graft versus Host Disease

Partnerships

Major investors

Financials

Market cap: $1.1B
Total revenue: $676K
Enterprise value: $848.6M

Beyond the preview

Go deeper on VectivBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VectivBio.

Explore the full profile